Everence Capital Management’s Biogen BIIB Stock Holding History

Everence Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$632K	Hold	3,450	–	–	0.04%	316
2025 Q4	$607K	Hold	3,450	–	–	0.04%	333
2025 Q3	$483K	Sell	3,450 -2,240	-39%	-$303K	0.03%	405
2025 Q2	$715K	Buy	5,690 +1,330	+31%	+$166K	0.05%	287
2025 Q1	$597K	Hold	4,360	–	–	0.04%	319
2024 Q4	$667K	Buy	4,360 +1,570	+56%	+$265K	0.04%	295
2024 Q3	$541K	Sell	2,790 -2,210	-44%	-$462K	0.03%	405
2024 Q2	$1.07K	Hold	5,000	–	–	0.07%	213
2024 Q1	$1.08K	Hold	5,000	–	–	0.07%	230
2023 Q4	$1.29M	Buy	5,000 +1,050	+27%	+$258K	0.09%	192
2023 Q3	$1.01K	Hold	3,950	–	–	0.08%	208
2023 Q2	$1.17M	Hold	3,950	–	–	0.1%	180
2023 Q1	$1.1K	Hold	3,950	–	–	0.09%	199
2022 Q4	$1.09K	Buy	3,950 +90	+2%	+$25.4K	0.09%	186
2022 Q3	$1.03M	Hold	3,860	–	–	0.1%	184
2022 Q2	$787K	Sell	3,860 -1,470	-28%	-$301K	0.07%	226
2022 Q1	$1.12M	Sell	5,330 -1,820	-25%	-$396K	0.09%	191
2021 Q4	$1.72M	Buy	7,150 +3,570	+100%	+$918K	0.13%	139
2021 Q3	$1.01M	Hold	3,580	–	–	0.08%	198
2021 Q2	$1.24M	Hold	3,580	–	–	0.1%	174
2021 Q1	$1M	Hold	3,580	–	–	0.09%	188
2020 Q4	$877K	Sell	3,580 -230	-6%	-$59.3K	0.09%	193
2020 Q3	$1.08M	Hold	3,810	–	–	0.12%	146
2020 Q2	$1.17M	Hold	3,810	–	–	0.14%	127
2020 Q1	$1.21M	Hold	3,810	–	–	0.17%	110
2019 Q4	$1.13M	Sell	3,810 -646	-14%	-$179K	0.17%	122
2019 Q3	$1.04M	Hold	4,456	–	–	0.17%	126
2019 Q2	$1.04M	Hold	4,456	–	–	0.17%	127
2019 Q1	$1.05M	Sell	4,456 -212	-5%	-$66.8K	0.18%	119
2018 Q4	$1.41M	Hold	4,668	–	–	0.33%	77
2018 Q3	$1.65M	Hold	4,668	–	–	0.33%	73
2018 Q2	$1.35M	Hold	4,668	–	–	0.29%	84
2018 Q1	$1.28M	Hold	4,668	–	–	0.28%	94
2017 Q4	$1.49M	Buy	4,668 +566	+14%	+$182K	0.33%	76
2017 Q3	$1.28M	Hold	4,102	–	–	0.29%	98
2017 Q2	$1.11M	Hold	4,102	–	–	0.27%	106
2017 Q1	$1.12M	Hold	4,102	–	–	0.29%	92
2016 Q4	$1.16M	Sell	4,102 -705	-15%	-$209K	0.33%	86
2016 Q3	$1.5M	Hold	4,807	–	–	0.45%	58
2016 Q2	$1.16M	Hold	4,807	–	–	0.36%	74
2016 Q1	$1.25M	Hold	4,807	–	–	0.39%	72
2015 Q4	$1.47M	Hold	4,807	–	–	0.48%	55
2015 Q3	$1.4M	Buy	4,807 +436	+10%	+$144K	0.48%	54
2015 Q2	$1.77M	Hold	4,371	–	–	0.57%	46
2015 Q1	$1.79M	Hold	4,371	–	–	0.6%	42
2014 Q4	$1.48M	Sell	4,371 -488	-10%	-$158K	0.51%	52
2014 Q3	$1.67M	Hold	4,859	–	–	0.61%	43
2014 Q2	$1.53M	Hold	4,859	–	–	0.57%	49
2014 Q1	$1.49M	Sell	4,859 -530	-10%	-$168K	0.59%	47
2013 Q4	$1.51M	Sell	5,389 -530	-9%	-$137K	0.61%	44
2013 Q3	$1.43M	Hold	5,919	–	–	0.61%	46
2013 Q2	$1.27M	Buy	+5,919	New	+$1.26M	0.58%	47

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Everence Capital Management's BIIB Position: Q1 2026 in Review

Everence Capital Management held its Biogen (BIIB) position steady in Q1 2026 at 3,450 shares worth $632K. The position accounts for 0.04% of the portfolio, ranked #316.

Everence Capital Management first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.79M in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Everence Capital Management held 3,450 shares of Biogen worth $632K as of Q1 2026.
Everence Capital Management left its Biogen share count unchanged in Q1 2026.
Biogen made up 0.04% of Everence Capital Management's portfolio in Q1 2026, its #316 holding.
Everence Capital Management first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
Everence Capital Management's Biogen position peaked at $1.79M in Q1 2015.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.